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Background. Alzheimer’s disease (AD) is the most common cause of dementia in elderly patients. Recently, several studies have
shown that inflammation and oxidative stress precede the cardinal neuropathological manifestations of AD. In view of the
proven antioxidant effects of probiotics, we proposed that continuous dietary supplementation with milk fermented with kefir
grains might improve cognitive and metabolic and/or cellular disorders in the AD patients. Methods. This study was designed as
an uncontrolled clinical investigation to test the effects of probiotic-fermented milk supplementation (2mL/kg/daily) for 90 days
in AD patients exhibiting cognitive deficit. Cognitive assessment, cytokine expression, systemic oxidative stress levels, and blood
cell damage biomarkers were evaluated before (T0) and after (T90) kefir synbiotic supplementation. Results. When the patients
were challenged to solve 8 classical tests, the majority exhibit a marked improvement in memory, visual-spatial/abstraction
abilities, and executive/language functions. At the end of the treatment, the cytometric analysis showed an absolute/relative
decrease in several cytokine markers of inflammation and oxidative stress markers (⋅O2
–, H2O2, and ONOO
−, ~30%)
accompanied by an increase in NO bioavailability (100%). In agreement with the above findings by using the same technique,
we observed in a similar magnitude an improvement of serum protein oxidation, mitochondrial dysfunction, DNA
damage/repair, and apoptosis. Conclusion. In conclusion, we demonstrated that kefir improves cognitive deficits, which seems to
be linked with three important factors of the AD—systemic inflammation, oxidative stress, and blood cell damage—and may be
a promising adjuvant therapy against the AD progression.
1. Introduction
Alzheimer’s disease (AD) is the most common cause of
dementia in elderly patients and is clinically defined as a
progressive, global, and strong cognitive decline leading to
an emotional distress and codependence [1–4]. Unfortu-
nately, the number of AD patients has been rapidly growing
worldwide (increasing by 117% in the last 26 years), with the
highest age standardized prevalence in Turkey and Brazil [5].
The pathophysiology of AD is multifactorial, involving
microglial activation, excessive proinflammatory cytokines, vas-
cular disorder, disrupted mitochondrial function accompanied
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by overproduction of reactive oxygen species (ROS), and
oxidized molecules [6–13]. In this scenario, the cardinal neuro-
pathological manifestations of AD culminate with amyloid-β
(Aβ) and neurofibrillary tangles (NFTs) composed of hyper-
phosphorylated tau protein leading to synapse degeneration
[9, 14, 15].
As the actual pharmacotherapy for dementia (using
cholinesterase and/or glutamate inhibitors) is insufficient in
slowing down completely the AD progression, new treatment
strategies are still necessary to improve AD patient care [5,
16, 17]. In parallel, there is growing evidence that distur-
bances along the “brain-gut-microbiota axis” are involved
in the pathogenesis of neurodegenerative diseases enhancing
inflammation at the gut, systemic, and central nervous
system (CNS) levels [15, 18]. In this context, recent data have
shown the beneficial effects of probiotic supplementation on
intestinal epithelial integrity, immunomodulation, oxidative
stress, and even procognition [15, 19, 20]. However, the role
of safe and inexpensive nutraceutical synbiotic kefir (a syner-
gistic mixture of prebiotics and probiotics) in AD is still not
documented [15, 20, 21].
The kefir-fermented milk is a functional food originally
from the Northern Caucasus and currently distributed
worldwide either commercially (e.g., Russia, Spain, Germany,
United States, Canada, and Brazil) or “in-house” [22–26].
Milk fermentation with kefir grains is made up by bioactive
compounds (peptides, vitamins, and polysaccharides)
originally generated by acid lactic bacteria and yeast species
present in these grains [23, 24, 26–28]. Recently, we and
others have shown that administration of kefir and/or their
bioproducts was able to prevent the cardiac and vascular
dysfunctions in experimental models of hypertension [23,
26, 29], atherosclerosis [30], and gastric ulcers [27], which
was justified, at least in part, by its antioxidative and immu-
nomodulatory properties.
The present study addressed the hypothesis that kefir
supplementation would provide cognitive benefit by attenu-
ating systemic inflammation and oxidative stress in AD
patients. The novel data revealed relevant new insights into
the effects of this synbiotic on cognitive function through
biochemical, molecular, and cellular parameters related to
neurodegenerative diseases.
2. Methods
2.1. Patients. This uncontrolled clinical trial evaluated AD
patients selected by convenience sampling. The diagnosis of
AD was according to the clinical diagnostic criteria of
dementia due to probable Alzheimer’s disease with increased
level of certainty defined by the Alzheimer’s Association and
the National Institute on Aging (NIA) published in 2011
[31]. The criteria evaluated in our study were based on the
presence of insidious cognitive progressive decline or
behavior symptoms involving a minimum of two cognitive
domains (e.g., memory, language, attention, and constructive
abilities) besides impairment of usual activities. It is impor-
tant to emphasize that unexplained symptoms by delirium
or major psychiatric disorders are detected through a combi-
nation of history taking and objective cognitive assessment.
The sample included individuals of both sexes, without age
restriction, who were assisted at a reference center in Vila
Velha, Espírito Santo, Brazil, specialized in AD. The
inclusion criteria were the following: (1) patients without
previous neurological and/or psychiatric comorbidities
associated with cognitive impairment, (2) patients without
clinical depression and/or with a depression index < 17 using
the Hamilton scale, and (3) patients without several clinical
comorbidities (decompensated diabetes) and patients with
autoimmune diseases taking or not immunosuppressive
medication, neoplasms, and/or inflammatory bowel diseases.
The exclusion criteria were the following: (1) patients unable
to make use of probiotic supplementation because of organic
or environmental causes, (2) patients using substances that
might affect neurocognitive assessment, and (3) patients
not using the maximum dose of acetylcholinesterase inhibi-
tor (donepezil, 10mg/day). The research was approved by
the ethics committee of Vila Velha University (#1.804.392),
and a signed free informed consent form was obtained from
each of the subjects and/or their tutors after complete
information about the nature and possible risks and benefits
of the study, for him/herself, the community, and medical
science was given.
In the beginning of the study, thirty-four subjects fulfilled
the inclusion criteria. However, eighteen subjects were
excluded from the study due to the elevated depression
indexes (three subjects), due to clinical and laboratory signs
of decompensated diabetes (six subjects), and due to the
intervention with antibiotic therapy and/or hospitalization
during the follow-up (nine subjects). During the study, 3
out of 16 patients in the final group died and a total of 13
subjects completed the experiments receiving the probiotic
supplementation for 90 days and being evaluated, as summa-
rized in Figure 1.
2.2. Production of Fermented Milk by Kefir Grains. The
fermented material was prepared by inoculating pasteurized
milk with 4% kefir grains containing the species Acetobacter
aceti, Acetobacter sp., Lactobacillus delbrueckii delbrueckii,
Lactobacillus fermentum, Lactobacillus fructivorans, Entero-
coccus faecium, Leuconostoc spp., Lactobacillus kefiranofa-
ciens, Candida famata, and Candida krusei and incubating
the culture at 25°C–28°C for 24 h. After the incubation
period, the fermented product was filtered and refrigerated
at 2°C–6°C for 24 h, as previously described by us [23]. In
order to improve organoleptic characteristics, the product
was blended with organic strawberries in the proportion of
500 g of fruit for every 2 L of fermented milk without added
sugars or preservatives.
2.3. Experiment Protocol. At first (T0), the participants were
submitted to a battery of tests for the screening of the identi-
fication of cognitive deficits and their venous blood was
collected for analysis of inflammation, oxidative stress, and
molecular and cellular integrity. The blood samples were
collected in EDTA-containing Vacutainer glass tubes
(Becton, Dickinson and Company, Franklin Lakes, NJ) and
centrifuged at 2000 g for 10min, and the serum was then
stored at −20°C. In addition, erythrocytes were lysed and
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white blood cells were stored at -80°C. All the measurements
were obtained via an automatic biochemical analyzer (AU
400 or 680, Olympus/Beckman Coulter, Munich, Germany)
or a flow cytometer (FACSCanto II, BD, CA, USA). These
data were considered the control values in this paired study.
After, the patients were subjected to fermented milk sup-
plementation at the daily dose of 2mL per kilogram of
body weight. At the end of the study (T90), the cognitive,
biochemical, molecular, and cellular parameters were once
again evaluated.
2.4. Cognitive Assessment. Cognitive assessment was made
before (T0) and after 90 days (T90) of the probiotic supple-
mentation, using the tests recommended by the Department
of Cognitive Neurology and Aging of the Brazilian Society of
Neurology for screening dementia syndromes [32], as well as
by the American Society of Neurology [33] and the National
Institute on Aging and Alzheimer’s Association [34]. The
following functions were analyzed: “global cognitive
functions,” using the (1) Mini-Mental State Examination
(MMSE); “memory,” using a recall board with 10 concrete
objects to promote the (2) immediate memory test and (3)
delayed memory test, according to Nitrini et al. [32], which
is recommended for evaluating populations with different
levels of education; “visual-spatial and abstraction abilities,”
using the (4) Cookie Theft Picture Test, according to the
consensus recommendations published by Nitrini et al. [32]
suggesting the use of description of thematic figures justified
by the absence of studies in the area with the Brazilian
population, and the (5) Similarity Test, using the recommen-
dations published by Nitrini et al. [32] to apply NEUROPSI
subsection where the respondent is asked to say the similarity
between three pairs of nouns (orange and pear, dog and
horse, and eye and nose); “executive and language functions,”
using the (6) Boston Naming Test and (7) verbal fluency test;
“attentive function,” using (8) Trail Making Test A; and
“visuoconstructive abilities,” using the (9) clock-drawing test.
To avoid the learning effect bias, the cognitive assessment
trials were spaced by 90 days and the various domain tests
were applied on a different order.
2.5. Determination of Cytokines Using the Cytometric Bead
Array. Concentrations of proinflammatory (IL-6, IL-8, IL-
1b, IL-12p70, and TNF-α) and anti-inflammatory (IL-10)
cytokines were analyzed in the serum of patients using a
Cytometric Bead Array Human Inflammation kit (CBA,
BD Biosciences, USA) according to the manufacturer’s
instructions. Samples were analyzed with a FACSCanto II
flow cytometer (BD, San Jose, CA, USA). Data acquisition
was performed with FACSDiva software (BD), and the
analysis of the events acquired was performed with the help
of FCAP Array software (BD). Samples were measured by
comparing them with the standard curves of recombinant
cytokines using FCAP Array software (BD). All results are
expressed as pg/mL.
2.6. ROS Analysis. Quantification of ROS components was
also performed by flow cytometry, using a FACSCanto II
(Becton Dickinson, BD, CA, USA) instrument to analyze
the intracytoplasmic ROS content, as previously described
by us [27, 35, 36]. Peripheral blood was drawn from the
Alzheimer’s patients, and the red blood cell lysis was induced
by the addition of ammonium chloride. Superoxide anion
(⋅O2
−), hydrogen peroxide (H2O2), peroxynitrite/hydroxyl
radical (ONOO−/⋅OH−), and nitric oxide (⋅NO) were
monitored separately by measuring changes in median
fluorescence intensity (MFI) emitted by dihydroethidine
(DHE), dichlorofluorescein (DCF), hydroxyphenyl fluores-
cein (HPF), and diaminofluorescein (DAF), respectively.
Briefly, 106 cells were incubated with 160mmol/L of DHE,
20mmol/L of DCF, 10 μmol/L of HPF, or 2μmol/L of DAF
at 37°C for 30min (DHE, DCF, and HPF) or 180min
(DAF) in the dark. The samples were then washed,
resuspended in PBS, and kept on ice until the acquisition of
10,000 events by flow cytometry, which were subsequently
analyzed using FCS Express software (De Novo).
2.7. Advanced Oxidation Protein Products. To determine
advanced oxidation protein products (AOPP), 40 μL of
plasma diluted in PBS (1.5) was added to 10μL of KI
(1.16mol/L) and 20μL glacial acetic acid and the absorbance
was read at 340nm in a microplate reader (Spectra-MAX-
190, Molecular Devices, Sunnyvale, CA, USA). The forma-
tion of triiodide ion through the oxidation of KI with













(death due to aging)
(n = 3)
Figure 1: Summary of exclusion criteria used in the present study and patient flow.
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expressed as μmol/mg of chloramine-T per mg of proteins,
according to Witko-Sarsat et al. [37].
2.8. Mitochondrial Membrane Potential (MMP). Estimation
of mitochondrial membrane potential (MMP) was
performed by flow cytometry using JC-10, a fluorogenic
probe (Sigma-Aldrich, USA), following the manufacturer’s
instructions. Briefly, 2 × 106 cells were loaded with 500 μL
of JC-10 solution at 37°C for 60min, protected from light.
For the positive control, cells were previously incubated with
carbonyl cyanide 3-chlorophenyl-hydrazone (CCCP, 5μM),
while unmarked cells were set as the negative control. JC-10
forms red J-aggregates in healthy cells but stays as a green
monomer in cells that have lost mitochondrial integrity.
The fluorescence intensities of JC-10 aggregates (red, FL2
channel) and monomers (green, FL1 channel) were
measured with flow cytometer detectors and analyzed after
compensation for spectral overlap. Data are expressed as
the relative aggregate/monomer (FL2/FL1) ratio, which was
assumed to be proportional to MMP intensity [38].
2.9. p53 and Cleaved PARP Expression. To determine the
expression of p53 and cleaved PARP, 2 × 106 cells were resus-
pended in Cytofix/Cytoperm (BD) solution and washed twice
with Perm/Wash buffer (BD). Blood cells were separately
incubated with 5 μL of anti-p53-FITC (BD) or anticleaved
PARP-PE, during 30min in the dark. As the positive control,
an aliquot of cells was treated with doxorubicin (25 μg/mL,
Sigma-Aldrich, USA) before antibody incubation. For the
staining control, we used specific immunoglobulins (IgG)
conjugated with FITC or PE. After antibody incubation, the
samples were stained with 10μL of 7-amino-actinomycin D
(7-AAD, BD). The determination of protein expression was
acquired with the FACSCanto II flow cytometer (Becton
Dickinson, San Jose, CA, USA) and analyzed using FCS
Express software (De Novo). Data are expressed as the
percentage of positive cells.
2.10. Cell Cycle Analysis. For the determination of cell cycle
distribution, 2 × 106 cells were resuspended in Cytofix/Cyto-
perm (BD) solution, washed with Perm/Wash buffer (BD),
and incubated with 10 μL of 7-amino-actinomycin D (7-
AAD, BD) for 30min, at 4°C, in the dark. The cell cycle
profile was determined by the acquisition of 10,000 events
per sample using the FACSCanto II flow cytometer for acqui-
sition and the FCS Express software for analysis. The sample
flow rate during acquisition did not exceed 200-300 cells per
second. Data are expressed as the percentage of cells in each
cell cycle phase, which are sub-G0-representing cells with
fragmented DNA (DNA content < 2n), G0/G1-representing
cells with 2n DNA, and S/G2/M-representing cells with
DNA content > 2n [35, 36].
2.11. Cell Viability and Apoptosis. Apoptotic cells were iden-
tified and quantified by flow cytometry using the Annexin
V-FITC/PI Apoptosis Detection kit (BD Bioscience)
according to the manufacturer’s instruction. Briefly, 106
blood cells were resuspended in binding buffer and incubated
for 15min at room temperature, in the dark, with 5 μL
annexin V-FITC and 5μL propidium iodide (PI). Data were
acquired using the FACSCanto II flow cytometer (BD) and
analyzed by the FCS Express software (De Novo). Double-
negative cells were considered viable, while annexin V-
FITC-positive cells were considered apoptotic [27, 35, 36].
Data are expressed as percentage of cells.
2.12. Statistical Analysis. All data are expressed as the mean
± SEM (except for the characteristics of patients, expressed
as means ± SD). The Kolmogorov-Smirnov test was applied
to assess the normal distribution of data. Considering that
all the samples had Gaussian distribution, Student’s t-test
for paired samples was used for the statistical analysis of
cytokine concentration, ROS, apoptosis indexes, and cell
viability before and after the administration of probiotic. p
values < 0.05 were considered statistically significant. Statisti-
cal analysis was performed using the GraphPad Prism
software, version 7.0.
3. Results
3.1. Characteristics of Patients (Demographic, Anthropometric,
and Social Characteristics). Table 1 shows the clinical
characteristics of elderly patients included in this study. No
significant differences between gender groups were observed
in relation to age, body mass index (BMI), treatment dura-
tion, and education level.
3.2. Cognitive Assessment. Figure 2 summarizes the results
of the cognitive tests divided into T0 and T90 time points.
We observed an improvement of performance in the
MMSE in 28% (T0: 17:4 ± 1:03 hits and T90: 22:3 ± 0:82
hits, p < 0:0001), indicating the benefits of kefir-fermented
milk on “global cognitive status” (Figure 2(a)). A similar
impact was observed on “memory analysis” (Figure 2(b), left
panel) through the immediate memory test (~66%, p < 0:05)
and late memory test (~62%, p < 0:05) between T0 and T90.
In the center of Figure 2(b), we also demonstrate the
improvement of “visual-spatial and abstraction abilities”
using the Similarity Test (~2-fold increase, p < 0:05) and
Cookie Theft Picture Test (~2-fold increase, p < 0:05).
Concerning the “executive and language functions”
(Figure 2(b), right panel), we also note a significant
increment through the Boston Test (~30%, p < 0:05) and ver-
bal fluency test (~25%, p < 0:05). Finally, the “cognitive
battery assay” showed a significant amelioration on the
constructive abilities, evidenced by the improvement on the
clock-drawing test (T0: 9:0 ± 2:4 hits and T90: 13:2 ± 2:3 hits,





(n = 2) p value
Age (years) 78:7 ± 3 78 ± 7 0.93
BMI (kg/m2) 25:8 ± 0:6 27 ± 1:7 0.61
Education level (years) 5:9 ± 0:6 5 ± 1:0 0.51
Treatment duration (years) 1:85 ± 0:7 0:6 ± 0:1 0.08
∗The values are presented as mean ± SD.
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p < 0:05), and on attentive function testified by the Trail
Making Test (40%, p < 0:05).
3.3. Cytokines. Figure 3 shows the quantification of some
cytokines involved in pathogenesis of neurodegenerative
diseases. The levels of proinflammatory cytokines TNF-α,
IL-8, and IL12p70 were lower at T90 than at T0 (~1.5-fold
decrease, respectively). However, other proinflammatory
(such as IL-1b and IL-6) or anti-inflammatory (IL-10)
cytokines did not show difference between T90 and T0. Inter-
estingly, analyzing the balance between proinflammatory and
anti-inflammatory cytokines (Figure 3(g)), we verified that
the probiotic supplementation was able to reduce the IL-
8/IL-10 and IL-12/IL-10 ratios (T0: 2:3 ± 0:2 vs. T90: 1:7 ±
0:1 pg/mL and T0 : 0:95 ± 0:05 vs. T90: 0:72 ± 0:08 pg/mL,
respectively, p < 0:05).
3.4. Direct and Indirect Oxidative Stress Biomarkers. Oxida-
tive stress was evaluated by flow cytometry trough DHE,
DCF, HPF, and DAF fluorescence. Figure 4 shows systemic
ROS production measured before and after kefir treatment.
We observed a significant decrease in serum levels of ⋅O2
-,
H2O2, and ONOO
-/OH- (Figure 4(a)) with a simultaneous


































































































Figure 2: Series of panels showing the results of the evaluation of cognitive tests before and after treatment using kefir (a fermented milk with
synbiotics). (a) Global cognitive status (by Mini-Mental State Examination (MMSE)) comparing the effect of the treatment with the previous
observed values. (b) Memory analysis (by immediate and late tests, left panel), visual-spatial and abstraction abilities (by Similarity Test and
Cookie Theft Picture Test, center panel), and executive and language functions (by Boston Naming Test and verbal fluency test, right panel).
(c) Cognitive battery assay, evaluated through constructive abilities and attentive function, with typical hand drawings of the patients during
the applied test. The results are expressed as mean ± SEM (n = 13). ∗p < 0:05 compared to T0.
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Figure 4(c) represents the mean values of systemic ⋅O2
- (T0:
5953 ± 999 vs. T90: 3622 ± 707, a.u.), H2O2 (T0: 4580 ± 611
vs. T90: 3202 ± 286, a.u.), ONOO-/⋅OH- (T0: 1161 ± 70 vs.
T90: 874 ± 34, a.u.), and NO (T0: 3493 ± 304 vs. T90: 1799
± 158) between T0 and T90.
Figure 5 shows the assessment of systemic protein oxida-
tion by AOPP (an important indirect biomarker of oxidative
stress). The results revealed that kefir administration leads to
a remarkable decrease in protein oxidation (T0: 8:4 ± 0:6 vs.
T90: 2:9 ± 0:3 μmol/mg).
3.5. Mitochondrial Membrane Potential (MMP). We further
evaluated whether the decrease in ROS production was
accompanied by a recovery of mitochondrial membrane
potential (MMP) due to kefir administration. The level of
membrane polarization after kefir treatment is shown in
Figure 6(a) (left panel). JC-10 green fluorescence (reflecting
mitochondrial dysfunction) significantly decreased, and JC-
10 red fluorescence (reflecting mitochondrial integrity)
increased after kefir consumption. Most of the cells shifted
towards the red fluorescence after kefir consumption indicat-
ing a significant preservation of mitochondrial function (T0:
0:11 ± 0:03 vs. T90: 2:0 ± 0:14, FL2/FL1, a.u.).
3.6. p53 Expression. The protein p53 is a transcription factor
that plays an important role in maintaining the genome
integrity by controlling cell apoptosis and cell cycle arrest
through signaling of genotoxic stress, like oxidative stress.
Figure 6(a) (right panel) shows the values of p53 expression







































































































Figure 3: Cytokine levels measured by the Cytometric Bead Array (CBA) using protocols performed through flow cytometry analysis. TNF-α
(a), IL-1b (b), IL-6 (c), IL-8 (d), IL-12p70 (e), IL-10 (f), and the ratio of proinflammatory/anti-inflammatory markers (g) were measured
before and after probiotic supplementation. The results are expressed as mean ± SEM (n = 13). ∗p < 0:05 compared to T0.
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treatment. As shown, p53 expression increased from T0
(10:1 ± 1:8%) to T90 (29:6 ± 2:9%).
3.7. Cell Cycle Arrest. Cell cycle distribution was determined
using flow cytometric analysis of blood cells. As shown in
Figure 6(b) (left panel), kefir consumption induced an
increase in the G0/G1 phase, indicating a cell cycle arrest in
T90 in comparison to T0 (T0: 61 ± 3:7 vs. T90: 92 ± 1:0%).
Simultaneously, we observed a decrease in the percentage of
cells in S/G2/M phases of the cell cycle after kefir consump-
tion (data not shown).
3.8. DNA Fragmentation. Results showed a significant
decrease in cells with sub-G0 DNA content after kefir treat-
























































































































Figure 4: Superoxide anion, hydrogen peroxide, peroxynitrite/hydroxyl radical, and nitric oxide levels measured by specific biomarkers
commonly used to evaluate ROS (DHE, DCF, HPF, and DAF staining, respectively). Records of ROS production were made before and
after 90 days of the probiotic supplementation. Note a marked recovery of the ROS imbalance after the treatment. The results were





















Figure 5: Levels of advanced oxidative protein products before and
after probiotic supplementation. The results are expressed as mean
± SEM (n = 13). ∗p < 0:05 compared to T0.
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determine whether kefir was capable of protecting DNA from
damage in cells undergoing increased ROS production. As
shown in Figure 6(b) (right panel), kefir administration was
able to reduce DNA fragmentation from 15:5 ± 1:3% in T0
to 5:2 ± 0:4% in T90. This finding suggests significant
changes in cell cycle progression and induction of apoptosis.
3.9. Cleavage of PARP-1. Poly (ADP-ribose) polymerase 1
(PARP-1) is involved in several biological processes, such as
cell cycle progression, DNA repair and regulation of tran-
scription, and programmed cell death. Proteolytic cleavage
of PARP is considered a hallmark of apoptosis, since
PARP-1 is cleaved by activated apoptotic caspases. Our flow
cytometry analysis showed a significant reduction in the per-
centage of cleaved PARP-1 after kefir consumption (T0:
20:2 ± 1:3 vs. T90: 4:8 ± 0:4%) (Figure 6(c), left panel).
3.10. Apoptosis Assay. Flow cytometry was used to determine
the antiapoptotic effect of kefir by quantification of annexin
V-positive cells. Phosphatidylserine (PS) is externalized and
available for detection by annexin V when cells undergo
apoptosis. After kefir treatment, the percentage of annexin
V-positive cells decreased in T90 (6:86 ± 1:91%) compared
to T0 (12:88 ± 1:91%) (Figure 6(c), right panel); conse-
quently, majority of cells were negative for annexin V
indicating their healthy status. The viable-to-apoptotic cell
ratio (V/A ratio) was 2.05, and the mean V/A ratio increased
from 6.53 at T0 to 13.39 at T90.
4. Discussion
In 1908, a Russian zoologist named Metchnikoff (the Nobel










































































































































⁎ p = 0.0002Apoptosis
(c)
Figure 6: Different evidences that kefir supplementation protects against cellular damage. The mitochondrial membrane potential (MMP)
and p53 expression (a), followed by induced cell cycle arrest and DNA repair (b), accompanied by a marked decrease in apoptosis (c). The
results are expressed as mean ± SEM (n = 13). ∗p < 0:05 compared to T0.
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first time the consumption of probiotics in the form of yogurt
as a “healthy food” [39–41]. However, only 100 years later, it
has been recognized that probiotics may influence CNS
function via the microbiota-gut-brain axis [19, 42, 43]. Even
so, clinical investigations using probiotics in elderly patients
with dementia are still scarce in medical literature [15]. In
this context, our study is the first to evaluate the beneficial
effects of kefir supplementation (at the minimum dose of
2mL/kg for 90 days) on cognitive function, biomarkers of
systemic oxidative stress, inflammation, and cell damage in
elderly patients with AD.
Although it is known that AD patients are susceptible
to multiple complications related to cognitive performance,
the innovative therapeutic strategies to reverse this progres-
sion are still scant. Interestingly, our results with kefir
supplementation for 3 months improved all cognitive tests
applied in our experiment (memory, visual-spatial function
and abstraction abilities, executive and language functions,
constructive abilities, and attentive function). Our results
corroborate the findings of Akbari et al. [19] that also
demonstrated that probiotic milk (containing Lactobacillus
acidophilus, Lactobacillus casei, Bifidobacterium bifidum,
and Lactobacillus fermentum) for 12 weeks are able to
improve the cognitive function. More recently, Kobayashi
et al. [44] reported that oral 24-week supplementation with
Bifidobacterium breve A1 improved cognitive function in
AD patients. As suggested by others, we speculated that
kefir supplementation also could alter the gut microbiota
contributing to neuromodulation through neuroactive and
neuroendocrine synthesis (e.g., acetylcholine, dopamine,
serotonin, norepinephrine, adrenaline, glutamate, gamma-
aminobutyric acid, and brain-derived neurotrophic factor
(BDNF)) besides their related receptor expression [15, 19,
45–49]. This hypothesis is partially based on early findings
in AD patients using multispecies probiotic intake (for 1
month) improving gut bacteria composition and serum
tryptophan levels, an amino acid precursor in serotonin
and melatonin biosynthesis [50]. Moreover, experimental
evidences support this idea demonstrating decreased level
of serum serotonin, BDNF, and NMDA receptors in
germ-free mice compared to conventional mice [19, 51,
52] and that Lactobacilli supplementation can increase
GABA availability from glutamate [53]. More recently,
another data demonstrated in mice revealed that the gut
microbiota is a potent influencer of BDNF in cortical and
hippocampal areas, besides increasing striatal monoamine
turnover and modulating the expression of serotonin recep-
tor 1A [48, 54]. Despite all these neuromodulatory benefits
previously described, it is believed that the influence on
inflammation and oxidative stress by probiotics may also
contribute to the neuroprotective effect, thus justifying the
next step of this study.
Neuroinflammation has been observed as another rele-
vant player in AD pathogenesis in both experimental and
clinical studies [11, 12, 55–59]. Numerous data demonstrate
positive associations between proinflammatory cytokines
(e.g., IL-1, IL-6, TNF-α, IL-8, and IL-12) and the progression
of AD [58, 60]. Moreover, recent investigations reported that
these neuroinflammatory cytokines can compromise the
clearance of Aβ, accumulating this toxic protein in the brain
[57, 58, 61–63]. Thus, cytokine balance has been an impor-
tant research target for understanding the pathophysiology
of AD and identifying new potential therapeutic targets. At
the same time, emerging data have shown that probiotics
can secrete metabolites and factors with immunomodulatory
properties [24, 48, 64]. For example, relevant studies demon-
strated a decrease in proinflammatory cytokines using multi-
strain probiotic supplementation [21, 65, 66]. The novelty in
our study was that we used an inexpensive food (and easily
produced at home) to reduce serum proinflammatory cyto-
kines and possibly contribute to neuroprotective effect in
AD patients. This immunosuppressive profile is reinforced
by other recent study from our lab using only nonbacterial
fraction of kefir in dyslipidemic mice [30], which allows us
to speculate that this immunomodulation could be the result
of a synergistic effect between microorganisms and soluble
products present in kefir.
Increased levels of serum oxidative stress biomarkers
reported in neurodegenerative diseases [11, 19, 67–71] seem
to be an interesting approach to evaluate the impact of new
therapeutic strategies in AD patients. At the same time, there
is a strong correlation of antioxidant-rich diets as an “easy”
strategy for neuroprotection [11, 17, 72, 73], including
probiotics [19, 21]. In this study, the assessment of serum
oxidative stress by direct and indirect methods (ROS and
AOPP) demonstrates that kefir has significant antioxidant
effects, helping to explain the favorable result concerning
cognition in AD patients. It is known that excessive ROS
are involved as a cause and consequence of proinflammation
contributing directly and indirectly to the pathogenesis of
AD [8, 17, 74–76]. More specifically, due to their electroneg-
ativity and reactivity, ⋅O2
−, H2O2, and ONOO
−/⋅OH− can
oxidize lipids, nucleic acids, and proteins leading to mito-
chondrial destruction, neuroexcitotoxicity (e.g., excessive
Ca2+ influx and formation of aggregates of toxic proteins),
and stimulation of microglia and astrocytes to develop
inflammatory response [17, 24, 36, 77]. On the other hand,
NO (by eNOS or nNOS isoforms) seems to be a “ROS-
gasotransmitter” with important neuroprotective properties
such as antioxidant (acting as a scavenger of ⋅O2
−), vasodila-
tor (increasing cerebral blood supply to neurons), inhibitor
of NMDA receptors at glutamatergic synapses (thereby pre-
venting neuroexcitotoxicity), and preventing the deposition
of Aβ [10, 78–81]. Interestingly, our findings demonstrate
for the first time that kefir reduces serum ROS bioavailability
accompanied by an NO increase reflecting the reduction of
plasma protein oxidation in AD patients. These data may
be supported by experiments of Musa et al. [21] that revealed
an increase in the activity of antioxidant enzymes (SOD,
GSH, and GPx) in the brain tissue of mice treated with
Lactobacillus. Therefore, all these results motivated us to
investigate the impact of mitochondrial and cell damage
obtained by the same blood samples from the same subjects.
It is known that AD brain mitochondria develop
diminished membrane potential, disrupting the electron
transfer chain, favoring excess ROS production, alteration
in cytosolic calcium homeostasis, and Aβ accumulation
leading to neurodegeneration [11, 72, 82–85]. In parallel,
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Delbarba et al. [86] demonstrated that mitochondrial DNA
can decrease in peripheral blood in the early stages of neuro-
degenerative disease progression, being a potential “blood-
based signature” in AD patients. Therefore, since several
studies of mitochondrial damage in Alzheimer’s patients
are performed postmortem, the possibility of exploring blood
samples in clinical investigations (as in the present study)
may be a promising strategy for establishing mechanisms
related to cognitive improvement with immunomodulatory,
antioxidant, and/or mitochondrial function. Interestingly,
we observed that kefir was able to reverse the compromised
mitochondrial membrane potential in blood cells of AD
patients, helping to explain (at least in part) the reduction
of ROS bioavailability in the same patients. Furthermore, in
this same context, as it is known that p53 under lower ROS
levels can contribute to cellular survival [87–89], we
confirmed this protective effect by kefir in AD patients
through 2 evidences: (1) by induction of DNA repair and
(2) by reduction of apoptosis. Firstly, we may affirm this
beneficial effect through a decrease in DNA fragmentation
accompanied by induction of cell cycle arrest after 90 days
of supplementation. Secondly, the reduction of apoptosis by
kefir was detected through a reduction of cleaved PARP-1
(considered to be a classical hallmark of apoptosis) and by
a decrease in annexin V-positive cells [36, 90]. In summary,
our data indicate that kefir supplementation has also a
mitochondria-protective effect in addition to cytoprotective
and antiapoptotic action, whose effects try to mitigate the
progression of neurodegeneration (Figure 7).
This study had some potential methodological limita-
tions. First, due to difficulties in obtaining fresh fecal
samples, we had problems with analysis of the fecal microbi-
ota before and after the kefir supplementation in our AD
patients. Second, our study was conducted without control
participants using other type of fermented milk. Third, the
sample size was small, but justified by age of the patients,
and it was accompanied by severe exclusion criteria. Addi-
tionally, the impact of learning effect bias was minimized
through randomized procedures applied in the cognitive
tests in the present study. Lastly, but not least, we could have
enriched the data exploring imaging biomarkers (e.g.,
magnetic resonance imaging and PET) or specific bio-
markers (e.g., brain-derived neurotrophic factor, neuronal
butyrylcholinesterase, and apolipoprotein A1) which would
extend the possible beneficial effects induced by chronic
kefir administration in these AD patients. Despite these
limitations, the novelty of our study is to demonstrate the
beneficial effects of chronic kefir supplementation on the
cognitive function in the elderly with AD.
5. Conclusion
The current study demonstrated that synbiotic supplementa-
tion for 90 days to older patients with AD had reparatory
favorable effects on cognitive dysfunction (improving
memory, language, executive functions, visual-spatial
function, conceptualization, and abstraction abilities),






























Executive and language functions
Figure 7: Beneficial effects of kefir on dementia in AD patients. Simplified scheme of main effects after 90 days with kefir supplementation on
Alzheimer’s subjects.
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cytokines), systemic oxidative stress (verified by a decrease in
ROS and AOPP), and blood cell damage (analyzed by DNA
damage/repairment and apoptosis). Therefore, the data of
the present study is opening a great opportunity for the eval-
uation of the clinical benefits of probiotics/synbiotics at
larger randomized controlled clinical trials, strengthening
the present valuable findings.
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